

# Reference List



Bates L, McGreevy A, Robinson E, Polokaova A, Adams E. Modelling Report: EU27 status towards 2030 HIV transmission elimination, 2026 report. Aquarius Population Health. April 15, 2026. <https://aquariusph.com/reports/eu27-status-towards-2030-hiv-transmission-elimination-2026-report/>

Di Marco F, Shahaj O, Valipour A, et al. Single-Inhaler Triple Therapy in Primary Care Across Europe: Expert Panel Consensus on the Consequences of Payer-Driven Access Rules and Call to Action. *Int J Chron Obstruct Pulmon Dis*. 2025 May 10.2147/COPD.S503726. eCollection 2025. <https://pubmed.ncbi.nlm.nih.gov/40433396/>

Doyle JS, Rockstroh JK, Keen P, et al. Cost-effectiveness of Emergency Department opt-out BBV testing to advance elimination targets for Viral Hepatitis and HIV transmission: Tales from opposite corners of the world. Poster presented at AASLD Conference; 7-11th November 2025, Washington DC, USA.

Rockstroh JK, Stocker H, et al. Estimating the health impact and cost-effectiveness of emergency department opt-out testing for blood-borne viruses in Germany. Poster presented at EACS Conference; 15-18th October 2025, Paris, France. EACS Abstract 2025 - 2025 - HIV Medicine - Wiley Online Library

Couillard S, Lugogo NL, Winders TA, et al. Modelling the impact of earlier biologic initiation in severe asthma patients. Poster presented at European Respiratory Society Congress 27<sup>th</sup> September – 1<sup>st</sup> October 2025, Amsterdam, Netherlands. [https://www.congresspublication.com/home/r---i/2025/ers-2025/ers2025\\_couillarddv-004472modelling-the-impact-of-earlier-biolog.html?qrcode=true](https://www.congresspublication.com/home/r---i/2025/ers-2025/ers2025_couillarddv-004472modelling-the-impact-of-earlier-biolog.html?qrcode=true)

Bates L, Polokaova A, Adams E. Modelling Report: The European Union's status towards HIV transmission elimination. Aquarius Population Health. September 19, 2025. <https://aquariusph.com/reports/modelling-report-the-european-unions-status-towards-hiv-transmission-elimination/>

McGreevy A, Bates L, Yajamin R, et al. How can England achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal. Aquarius Population Health; 1 Sept 2025. <https://aquariusph.com/reports/how-can-england-achieve-hiv-transmission-elimination-modelling-the-impact-of-current-hiv-prevention-efforts-on-progress-towards-the-2030-elimination-goal/>

Huntington SE, Bates L, Coukan F, Adams EJ. Estimating the number of people who could benefit from HIV pre-exposure prophylaxis (PrEP) in England and the unmet need. *Sex Transm Infect*. Published online July 6, 2025. doi:10.1136/sextrans-2024-056456

d'Arminio Monforte A, d'Ettore G, Galardo G, et al. Estimating the potential health economic value

of introducing universal opt-out testing for HIV in emergency departments in Italy. *Eur J Public Health*. Published online April 23, 2025. doi:10.1093/eurpub/ckaf057

Bates L, McGreevy A, Schneider V, et al. When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal. Poster presented at BHIVA Conference; 23rd-25th April 2025, Brighton, UK.

Huntington S, McGreevy A, Rebbapragada A, *et al.* First-void urine self-sampling for primary HPV cervical cancer screening: an implementation tool for US healthcare professionals. Poster presented at IPVC Conference; 12-13<sup>th</sup> November 2024, Edinburgh, UK.

Huntington S, Smith JS, Nuttall D, et al. Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening. *Future Oncology* 2024 Oct 24, 1–12. DOI: 10.1080/14796694.2024.2409625

Lani E, Polokaova A, Mercer K, et al. Understanding the use of mAbs for COVID-19 pre-exposure prophylaxis (PrEP) in patients with haematological malignancies - insights from clinician interviews in Germany. Poster presentation The European Society for Immunodeficiencies (ESID) meeting, 16-19th October 2024, Marseille, France.

d'Arminio Monforte A, d'Ettore G, Galardo G, et al. The potential health economic value of universal opt-out HIV testing in emergency departments in Italy. Oral presentation at Fast-Track Cities 2024; 13- 15th October 2024, Paris, France. [www.iapac.org/files/2024/10/1335-M-Ruf.pdf](http://www.iapac.org/files/2024/10/1335-M-Ruf.pdf)

Huntington S, et al. Estimating the gap between PrEP use and PrEP need in England. Oral presentation at HIV Prevention England Conference. Prioritising equity and impact. 6th September 2024. London, UK. <https://www.hivpreventionengland.org.uk/2024/09/11/hiv-prevention-england-conference-2024-presentations-and-talks/>

d'Arminio Monforte A, d'Ettore G, Galardo G, et al. OC-4 Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: a modelling study. *Sexually Transmitted Infections* 100(Suppl 1):A4-A5. DOI: 10.1136/sextrans-ICAR-2024.4. Oral presentation at 16th Italian Conference on AIDS and Antiviral Research, July 2024, Rome, Italy.

Shahaj O, Meiwald A, Puri Sudhir K et al. Mapping the Common Barriers to Optimal COPD Care in High and Middle-Income Countries: Qualitative Perspectives from Clinicians. *Int J Chron Obstruct Pulmon Dis*. 2024 May 30; doi: 10.2147/COPD.S449659..

Di Marco, F., Shahaj, O., Valipour, et al. Variations in the pharmacological management of COPD due to payer-driven access criteria for triple therapy: Pan-European cross-expertise qualitative insights. 12th International Primary Care Respiratory Group World Conference, 9-11th May 2024, Athens, Greece.

Navani N, van Doornewaard A, Schneider V, et al. 119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study. April 2024 <https://www.sciencedirect.com/science/article/abs/pii/S0169500224002253>

Puri Sudhir K, Kagenaar E, Meijer M et al. Comparing the costs and diagnostic outcomes of replacing cytology with the QIASure DNA Methylation Test as a Triage within HPV primary cervical cancer screening in The Netherlands. *Diagnostics*. 2023 Dec 6; 13(24):3612. doi:10.3390/diagnostics13243612

Dombrowski C, Bourgain C, Ma Y, et al. An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology (LBC) co-testing.

European Journal of Cancer Prevention. 2023 Nov 6; doi: 10.1097/CEJ.0000000000000856.

Pinsent A, Weston G, Adams EJ, et al. Determining the relationship between seizure-free days and other predictors of quality of life in patients with Dravet Syndrome and their carers from FFA registration studies. *Neurol Ther*. 2023 Jun 16; doi: 10.1007/s40120-023-00510-8.

Miners L\*, Huntington S\*, Lee N et al. An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain. *BMC Pulmonary Medicine*. Available from: <https://doi.org/10.1186/s12890-023-02516-2>

Huntington S, Puri Sudhir K, Schneider V, et al. Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation. *BMJ Open* 2023;13:e068940. Available from: <http://dx.doi.org/10.1136/bmjopen-2022-068940>

Jameel A, Meiwald A, Bain P, et al. The Cost-Effectiveness of unilateral magnetic Resonance-Guide focused ultrasound in comparison to unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. *BJR*. 2022 Sep 20; 20220137. Available from: <https://doi.org/10.1259/bjr.20220137>

Vankelegom M, Burke D, Mohammed AMF, et al. Cost-effectiveness of a rapid point-of-care test for diagnosing patients with suspected bloodstream infection in Ireland. *Informatics in Medicine Unlocked*. 2022 Jan 1; 32:101056. Available from: <https://www.sciencedirect.com/science/article/pii/S2352914822001952>

Dombrowski CA, Weston GM, Descamps PP, et al. Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme. *Medicine (Baltimore)*. 2022 Jul 22;101(29): e29530.

Meiwald A, Gara-Adams R, Rowlandson A, et al. Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care. *Int J Chron Obstruct Pulmon Dis*. 2022; 17:1507-1521 <https://doi.org/10.2147/COPD.S360983>

Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. *Therapeutic Advances in Infectious Disease*. January 2021. doi:10.1177/20499361211061645

Gara-Adams R, Mowlem F, Thomas RH, et al. Care Pathway Mapping for Dravet Syndrome (DS) Patients in England – interim results from a pilot study. Presented at: ILAE British Branch Virtual Annual Scientific Conference, September 23 – 24, 2021; Virtual

Meiwald A, Gara-Adams R, Ma Y, et al. Analysing the COPD care pathway in Japan, Canada, England and Germany: a global view. Presented at: European Respiratory Society International Congress 2021, September 5 – 8, 2021; Virtual

Weston G, Dombrowski C, Steben M, et al. A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. *Preventive Medicine Reports [Internet]*. 2021 Sep 1; 23:101448. Available from: <https://www.sciencedirect.com/science/article/pii/S2211335521001388>

Pinsent A, Weston G, Adams EJ, et al. Determining the Relationship of Seizures, Seizure Free Days and Other Predictors of Health Related Quality of Life in Patients with Dravet Syndrome (DS) and Their Carers. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual

Weston G, Pinsent A, Adams EJ, et al. A Cost Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual

Dombrowski C, Weston G, Adams E. Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Dombrowski C, Weston G, Adams E. Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Dombrowski C, Weston G, Descamps P, et al. Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Weston G, Steben M, Popadiuk C, Bentley J, et al. Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Kerry-Barnard S, Huntington, S, Fleming C, et al. Near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges: a cost analysis of the 'Test n Treat' feasibility trial. *BMC Health Services Research* (2020) 20:316 <https://doi.org/10.1186/s12913-020-5062-5>.

Weston G, Dombrowski C, Harvey MJ, et al. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. *BMJ Open* 2020;10:e031303. doi:10.1136/bmjopen-2019-031303

Micha A, Sinnett V, Wilson R, et al. P048. Interim analysis of an evaluation of clinical service impact of switching from wire to magnetic seeds for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Vol 45, Issue 5, 898. DOI: <https://doi.org/10.1016/j.ejso.2019.01.070>

Micha A, Sinnett V, Wilson R, et al. 30. Interim analysis of an evaluation of clinical outcome and patient and clinician satisfaction with magnetic seeds compared with guide wires for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Volume 45, Issue 5, 884. DOI: <https://doi.org/10.1016/j.ejso.2019.01.216>

Oakeshott P, Kerry-Barnard S, Fleming C, et al. "Test n Treat" (TnT): a cluster randomised feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical colleges. *Clin Microbiol & Inf.* Available 1 Nov 2018. doi.org/10.1016/j.cmi.2018.10.019.

Aquarius Population Health, on behalf of the British In Vitro Diagnostics Association (BIVDA) and Innovate UK. Three simple tests could save the NHS at least £6.9 billion. London. June 2018. [www.bivda.org.uk/3\\_simple\\_tests.pdf](http://www.bivda.org.uk/3_simple_tests.pdf)

Kerry-Barnard S, Fleming C, Reid F, et al. 'Test n Treat (TnT)' - Rapid testing and same-day, on-site treatment to reduce rates of chlamydia in sexually active further education college students: study protocol for a cluster randomised feasibility trial. *Trials*. 2018 Jun 5;19(1):311. doi: 10.1186/s13063-018-2674-8.

- Huntington SE, Burns RM, Harding-Esch E, et al. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *BMJ Open* 2018;8:e020394. doi: 10.1136/bmjopen-2017-020394
- Vecino-Ortiz AI, Goldenberg SD, Douthwaite ST, et al. Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward. *Diag Micro & Infect Dis* 2018. doi.org/10.1016/j.diagmicrobio.2018.03.013
- Harvey MJ, Cheng C-Y, Leone E, et al. Exploring HCV eradication through diagnosis and treatment strategies. EASL Monothematic Conference, Striving Towards the Elimination of HCV Infection. Berlin, Germany (2018).
- Adams EJ, Cheng C-Y, Sacco J, et al. Mapping the treatment pathway for metastatic uveal melanoma patients in England: A qualitative pilot study. Society for Immunotherapy of Cancer's 32nd Annual Meeting, Maryland, USA (2017).
- Cheng C-Y, Alamgir G, Adams EJ, et al. Quantifying standard of care (SOC) hospital-related resource utilisation for metastatic uveal melanoma (MUM) patients in NHS England (NHSE) using the hospital episodes statistics (HES) dataset. *Value in Health* 20, A514 (2017).
- Schwenkglens M, Alamgir G, Cheng, C-Y, et al. A real-world evidence (RWE) approach to characterising an ultra-rare disease (URD) cohort of metastatic uveal melanoma (MUM) patients within National Health Service England (NHSE). *Value in Health* 20, A730 (2017).
- Whitlock GG, Gibbons, DC, Longford N, et al. Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. *Int J STD & AIDS* 29(5):474-482 (Apr 2018). doi:10.1177/0956462417736431
- Harding-Esch E, Huntington SE, Harvey MJ, et al. Cost-effectiveness of antimicrobial resistance point-of-care testing for optimising the treatment of gonorrhoea. *Sex Transm Infect* 93, A34–A35 (2017).
- Harding-Esch E, Huntington SE, Burns RM, et al. Evaluating the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *Sex Transm Infect* 93, A205–A205 (2017).
- Turner KM, Christensen H, Adams EJ, et al. Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of *Neisseria Gonorrhoeae*: a modelling study. *BMJ Open* 7, e015447 (2017).
- Bustinduy AL, Jeyaratnam D, Douthwaite S, et al. Point-of-care tests for infectious diseases: barriers to implementation across three London teaching hospitals. *Acta Paediatrica* 106, 1192–1195 (2017).
- Vecino Ortiz AI, Glover R & Adams EJ. Modelling the burden of bladder cancer and monitoring cystoscopies in Europe. *European Urology Suppl* 15, e203 (2016).
- Adams EJ. How to prevent cervical cancer: HPV – we are coming to get you! EUROGIN, Salzburg, Austria. (2016).
- Vecino Ortiz AI, Glover RE, Douthwaite ST, et al. Estimating the clinical impact and costs of implementing a point of care test for influenza A/B and respiratory syncytial virus on an acute paediatric hospital inpatient ward. Society for Medical Decision Making, London, UK (2016).

- Vecino Ortiz AI, Glover RE, Rabe AJ, et al. A rapid influenza test in hospitals could avoid unnecessary paediatric isolation bed days and save cost. Society for Medical Decision Making, London, UK (2016).
- Douthwaite ST, Walker C, Adams EJ, et al. Performance of a novel point-of-care molecular assay for the detection of Influenza A, B and Respiratory Syncytial Virus (Enigma® MiniLab™) in children with acute respiratory infection. *J. Clin. Microbiol.* JCM.02887-15 (2015). doi:10.1128/JCM.02887-15
- Adams EJ, Midha D, Postulka A, et al. Mapping the diagnostic pathway for breast cancer in England and comparison to Europe. *Value in Health* 18, A477 (2015).
- Adams EJ, Kendall E, Horner PJ, et al. Thinking critically about the value and cost of drugs: an example from managing patients with invasive fungal disease. 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015), Copenhagen, Denmark (2015).
- Alexander H, Munro-Wild H, Richards P, et al. Providing integrated HIV treatment and care for stable patients in general practice. 21st Annual Conference of the British HIV Association, Brighton, UK (2015).
- Adams EJ, Glover R, Vecino Ortiz AI, et al. How can European countries improve cervical cancer prevention for women? 30th International Papillomavirus Conference, Lisbon, Portugal (2015).
- Adams, EJ, Glover R, Vecino Ortiz AI, et al. Exploring the value of a rapid, on-demand test for the detection of human papillomavirus. 30th International Papillomavirus Conference, Lisbon, Portugal (2015).
- Ceesay MM, Sadique Z, Harris R, et al. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. *J Antimicrob Chemother* 70, 1175–1181 (2015).
- Taylor R, Carlin E, Sadique Z, et al. The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study. *Int J STD AIDS* 26, 75–80 (2015).
- Horner P, Blee K & Adams EJ. Time to manage *Mycoplasma genitalium* as an STI: but not with azithromycin 1g! *Current Opinion in Infectious Diseases* 27, 68 (2014).BTW
- Price C, Adams EJ & Horner P. Point-of-care testing leads the way. *Parliamentary Review* (2014).
- Adams EJ, Ehrlich A, Turner KM, et al. Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open* 4, e005322 (2014).
- Hill C, Nasr R, Fisher MI, et al. Estimated cost and payment by results (PBR) tariff reimbursement for idiopathic pulmonary fibrosis services across 14 specialist providers in England. *British Thoracic Society Winter Meeting*, London, UK (2014).
- Adams E, Ogden D, Ehrlich A, et al. Treatment for stable HIV patients in England: can we increase efficiency and improve patient care? *J Health Serv Res Policy* 19, 131–137 (2014).
- Turner KM, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for *Chlamydia trachomatis* and *Neisseria gonorrhoea* in genitourinary medicine clinics in England. *Sex Transm Infect* 90, 104–111 (2014).
- Gillespie P, O’Neill C, Adams EJ, et al. The cost and cost-effectiveness of opportunistic screening for *Chlamydia trachomatis* in Ireland. *Sex Transm Infect* 88, 222–228 (2012).

Turner KM, Adams EJ, Grant A, et al. Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. *BMJ* 342, c7250 (2011).

Aghaizu A, Adams EJ, Turner KM, et al. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for *Chlamydia trachomatis*? Cost analysis of the prevention of pelvic infection (POPI) trial. *Sex Transm Infect* 87, 312–317 (2011).

W